Company Overview

Detailed company information

Basic Information

Ticker: XERS

Country: US

Headquarter: Chicago, IL

Employees: 435

Financial Information

Market Cap: $1.5 Billion

Currency: USD

Sector: Healthcare

Industry: Biotechnology

Stock Price Chart

Stock Data provided by Financial Modeling Prep

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.

Last Updated: Sep 2026

Here's what you can ask

Earnings Transcripts

Latest

Earnings Transcript for 2026 - Q2Released: Aug 06, 2026

Earnings Transcript for 2026 - Q1Released: May 07, 2026

Earnings Transcript for 2025 - Q4Released: Mar 02, 2026

Earnings Transcript for 2025 - Q3Released: Nov 06, 2025

Earnings Transcript for 2025 - Q2Released: Aug 07, 2025

Earnings Transcript for 2025 - Q1Released: May 08, 2025

Earnings Transcript for 2024 - Q4Released: Mar 06, 2025

Earnings Transcript for 2024 - Q3Released: Nov 08, 2024

Earnings Transcript for 2024 - Q2Released: Aug 08, 2024

Earnings Transcript for 2024 - Q1Released: May 09, 2024

Earnings Transcript for 2023 - Q4Released: Mar 06, 2024

Earnings Transcript for 2023 - Q3Released: Nov 09, 2023

Earnings Transcript for 2023 - Q2Released: Aug 08, 2023

Earnings Transcript for 2023 - Q1Released: May 09, 2023

Earnings Transcript for 2022 - Q4Released: Mar 08, 2023

Earnings Transcript for 2022 - Q3Released: Nov 09, 2022

Earnings Transcript for 2022 - Q2Released: Aug 10, 2022

Earnings Transcript for 2022 - Q1Released: May 11, 2022

Earnings Transcript for 2021 - Q4Released: Mar 10, 2022

Earnings Transcript for 2021 - Q3Released: Nov 10, 2021

Earnings Transcript for 2021 - Q2Released: Aug 05, 2021

Earnings Transcript for 2021 - Q1Released: May 12, 2021

Earnings Transcript for 2020 - Q4Released: Mar 09, 2021

Earnings Transcript for 2020 - Q3Released: Oct 31, 2020